The Inflation Reduction Act (IRA) is helping people with Medicare afford their medications, including the 2.1 million Asian, 5.8 million Black, and 5.3 million Latino Part D enrollees. These fact sheets review existing research to present the projected impacts of key IRA Medicare drug-related provisions for these populations.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 1 - 10 of 146. 10 per page. Page 1.
Advanced SearchFact Sheet
Inflation Reduction Act Research Series: Projected Impacts for Asian, Black, and Latino Medicare Enrollees
September 25, 2023
ASPE Issue Brief
Understanding Markets for Antimicrobial Drugs
August 31, 2023
Development of novel antimicrobials has slowed, and the preclinical and clinical pipeline is likely to be insufficient to support current and future patient needs.
Report
Emergency Department Interventions for Opioid Use Disorder
August 31, 2023
Emergency departments (EDs) are key partners in filling the gap between people who need opioid use disorder (OUD) treatment and people who ultimately receive it.
Fact Sheet
Inflation Reduction Act Research Series: Medicare Enrollees’ Use and Out-of-Pocket Expenditures for Drugs Selected for Negotiation under the Medicare Drug Price Negotiation Program
August 29, 2023
The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that have high total spending and are high expenditure, single source drugs without generic or biosimilar competition.
Report
Analysis of Market Challenges for Antimicrobial Drug Development in the United States
August 28, 2023
The market for antimicrobial (AM) drugs is unique in that it is associated with a positive externality (public health) as well as a negative externality (antimicrobial resistance, or AMR) (Mossialos, et al., 2010). AMR occurs when microbes change over time and no longer respond to available medicine.
Report
Antimicrobial Drugs - Market Returns Analysis
August 28, 2023
In 2017, at least 2.8 million people in the U.S. acquired serious infections with bacteria that are resistant to one or more antimicrobial drugs and 35,000 have died as a result. Resistance to antimicrobials is viewed as a global threat with antimicrobial drug use in human and animal health driving resistance.
Report
The Inflation Reduction Act of 2022: One Year Anniversary Highlights from ASPE Drug Pricing Reports
August 16, 2023
Introduction
Fact Sheet
State Fact Sheets: Impacts of the IRA and ACA on Lowering Health Care Costs
July 28, 2023
Expanding access to high-quality, affordable health care has been a priority of the Biden-Harris Administration.
Report
Inflation Reduction Act Research Series: Medicare Part D Enrollee Out-of-Pocket Spending: Recent Trends and Projected Impacts of the Inflation Reduction Act
July 6, 2023
The Inflation Reduction Act (IRA) will make key changes to improve drug affordability for people who have Medicare.
ASPE Issue Brief
Medicare Part B Drugs: Trends in Spending and Utilization, 2008-2021
June 9, 2023
The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research on spending and utilization trends of Medicare Part B drugs, drugs administered in physicians' office or hospital outpatient departments rather than being purchased at the pharmacy counter or by mail order.